INS and metabolic syndrome: PPARγ is an essential regulator of insulin sensitivity, lipid homeostasis, andinflammation and glucose metabolism and therefore it represents an important pharmacological target for drug discovery which canmodulate at once several various underlying pathologies of the MetS [10-11].The PPARγ activators have proven potent in combating hypertension and MetS [12-13,14].